Literature DB >> 20621591

Chemokine CXC Ligand 16 serum concentration but not A181V genotype is associated with atherosclerotic stroke.

Ke-di Wang1, Zhi-zhong Liu, Rui-min Wang, Ya-jie Wang, Guo-jun Zhang, Jian-rong Su, Xi-xiong Kang.   

Abstract

BACKGROUND: Serum chemokine CXC Ligand 16 (CXCL16) concentration is associated with atherosclerosis and CXCL16 expression may be influenced by the polymorphism, A181V. We established whether serum CXCL16 concentration or the A181V genotype is more strongly associated with atherosclerotic stroke and its associated risk factor, carotid atherosclerosis.
METHODS: PCR-RFLP was used to genotype 244 atherosclerotic stroke patients (AS group), 153 stroke-free controls (patient controls) and 167 healthy controls. Serum CXCL16 concentration was determined for a subset of patients (n=135) and all controls. The same subset of patients was then examined using ultrasound to evaluate their carotid atherosclerotic lesions, including intima-media thickness (IMT), plaque stability and carotid plaque area (CPA).
RESULTS: Compared with the patient controls and healthy controls, serum CXCL16 concentration was significantly increased in the AS group (P<0.05, and 0.01). It was also strongly associated with increased IMT, vulnerable plaque and increased CPA (P<0.05, <0.001, and <0.01). However, the CXCL16 A181V genotype distribution and allele frequencies showed no differences between AS and control groups, nor did it influence serum CXCL16 concentration.
CONCLUSION: Serum CXCL16 concentration is significantly associated with atherosclerotic stroke and carotid atherosclerosis, suggesting that this biochemical test may be useful to identify patients at increased risk of atherosclerosis. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20621591     DOI: 10.1016/j.cca.2010.05.033

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  The gender-specific association of CXCL16 A181V gene polymorphism with susceptibility to multiple sclerosis, and its effects on PBMC mRNA and plasma soluble CXCL16 levels: preliminary findings.

Authors:  Ljiljana Stojković; Aleksandra Stanković; Tamara Djurić; Evica Dinčić; Dragan Alavantić; Maja Zivković
Journal:  J Neurol       Date:  2014-05-23       Impact factor: 4.849

2.  Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study.

Authors:  L Turgunova; B Baidildina; Y Laryushina; B Koichubekov; A Turmukhambetova; L Akhmaltdinova
Journal:  Cardiol Res Pract       Date:  2020-06-23       Impact factor: 1.866

Review 3.  The Role of CXC Chemokines in Cardiovascular Diseases.

Authors:  Xiyi Lu; Zhen Wang; Di Ye; Yongqi Feng; Menglin Liu; Yao Xu; Menglong Wang; Jishou Zhang; Jianfang Liu; Mengmeng Zhao; Shuwan Xu; Jing Ye; Jun Wan
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

Review 4.  Regulation of atherogenesis by chemokines and chemokine receptors.

Authors:  Wuzhou Wan; Philip M Murphy
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-12-07       Impact factor: 4.291

5.  Exploring biomarkers associated with deteriorating vascular health using a targeted proteomics chip: The SABPA study.

Authors:  Anna Dieden; Leone Malan; Catharina M C Mels; Leandi Lammertyn; Annemarie Wentzel; Peter M Nilsson; Petri Gudmundsson; Amra Jujic; Martin Magnusson
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

6.  A Functional Variant of CXCL16 Is Associated With Predisposition to Sepsis and MODS in Trauma Patients: Genetic Association Studies.

Authors:  Jianhui Sun; Huacai Zhang; Di Liu; Li Cui; Qiang Wang; Lebin Gan; Dalin Wen; Jun Wang; Juan Du; Hong Huang; Anqiang Zhang; Jin Deng; Jianxin Jiang; Ling Zeng
Journal:  Front Genet       Date:  2021-09-03       Impact factor: 4.599

7.  Elevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke.

Authors:  Aijun Ma; Xudong Pan; Yubo Xing; Mei Wu; Yuan Wang; Cuiling Ma
Journal:  Arch Med Sci       Date:  2014-02-23       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.